<DOC>
	<DOCNO>NCT00934986</DOCNO>
	<brief_summary>Purpose : The involvement Natural Killer cell ( NK ) efficiency treatment lymphoma begin new therapy base function activation NK , justify improvement knowledge status population NK ( number , function , genic expression ) Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Natural Killer Cells Function Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Method : prospective , monocentric , descriptive study Primary objective : Evaluation expression function receptor activator NK cell ( KIRs ) patient CLL stage A therapeutic abstention , stage B C require treatment . Secondary objective : Measure evolution cytotoxic function NK cell biomarkers activation patient receives immunochemotherapy Rituximab/ Fludarabine/ Cyclophosphamide ( RCF ) . Verification , analysis , function biomarkers adaptive innate immunity</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Diagnosis CLL ( Score Matutes &gt; =4 ) history treatment : Stade A Binet , Or Stade B C begin treatment RFC Patients undergo blood collection Patient age 18 year old Signed consent Non inclusion Criteria : Patient anemia : haemoglobin &lt; 9 g/dl Pregnancy , breast feeding Patient urgent situation , unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>NK Cells</keyword>
</DOC>